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Edited by Jesus AvilaAbstract Diﬀerent types of cells from subjects with Down syn-
drome (DS) have an increased susceptibility to cell death. We
have studied apoptosis and mitochondrial (mt) membrane poten-
tial (DWm) in peripheral blood mononuclear cells (PBMC) from
DS children and age-matched healthy donors after in vitro treat-
ment with apoptogenic molecules, along with mtDNA content.
We found that PBMC from DS and healthy controls had a sim-
ilar tendency to undergo apoptosis and a similar amount of
mtDNA. However, in cells from DS subjects, mitochondria
showed a higher loss of DWm, underlying the presence of an
increasing susceptibility of these organelles to damaging agents.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis1. Introduction
Down syndrome (DS, trisomy 21) is the most frequent chro-
mosomal abnormality in live births and the most frequent
cause of mental retardation. This condition is associated with
a number of manifestations including heart defects, type I dia-
betes mellitus, hypotonia, increased susceptibility to bacterial
and viral infections and a precocious development of Alzhei-
mer disease, as well as several defects of the acquired immune
response [1–4].
Neurons from DS subjects display an increased susceptibility
to apoptosis [5–7]. Fetal DS neurons are also characterized by
high production of reactive oxygen species (ROS), that in turn
involve mitochondrial death pathway, as shown by increased
levels of bax, and cytoplasmic translocation of cytochrome c
and apoptosis inducing factor (AIF) [5,8].
Deletions, mutations or replication abnormalities of mito-
chondrial (mt) DNA due to genetic defects, hypoxia, oxidative*Corresponding author. Fax: +39 0 59 2055426.
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doi:10.1016/j.febslet.2006.12.058stress or age can impair mitochondrial function resulting in en-
ergy depletion and increased susceptibility to apoptosis [9].
Many alterations have been described in mitochondria of DS
subjects [10,11]. Astrocytes and ﬁbroblasts show decreased
mitochondrial redox activity and depolarization of mitochon-
drial membrane potential (DWm) [12]. This dysfunction could
be responsible of a higher vulnerability to exogenous toxic in-
sults, such as those provoked by ROS [5]. A decreased repair
of oxidative damage in mtDNA from DS ﬁbroblasts compared
to normal ﬁbroblasts has been reported, which leads to a
greater oxidative damage in mtDNA [10]. Lee et al. also
demonstrated an impairment in the levels of transcription of
the mitochondrial gene ATPase6 in DS fetuses compared
to control ones [13], which could aﬀect the generation of
ATP [11].
Peripheral blood mononuclear cells (PBMC) from DS sub-
jects are characterized by several alterations including impair-
ment in proliferative response to phytohemagglutinin [14],
defective production of interleukin-2 [15] and a signiﬁcant
reduction in IL-1b secretion after activation with LPS [16].
Since some of these alterations could be related to a reduced
mitochondria functionality, we analyzed diﬀerent parameters
related to mitochondrial functionality in PBMC from DS sub-
jects. In particular, we quantiﬁed the content of mtDNA per
cell and studied the behaviour of PBMC and mitochondria
after exposure to diﬀerent drugs, and compared these parame-
ters to those obtained in healthy donors.2. Materials and methods
2.1. Subjects
We studied a total of 16 children with DS with a mean age of 5.1
years (range: 1–16), 11 males and 5 females; as controls, we studied
a total of 24 karyotypically normal children with a mean age of 4.5
years (range: 1–10), 21 males and 3 females. All subjects were in
healthy conditions, without relevant acute or chronic disease aﬀecting
the immune system. Informed consent was obtained by their parents.
2.2. Cell culture
PBMC were isolated from a minimum of 5 ml freshly collected
blood according to standard procedures. PBMC were plated at the
density of 4 · 105 cells/ml in complete culture medium, i.e. RPMIblished by Elsevier B.V. All rights reserved.
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2 mM L-glutamine, 100 IU/ml penicillin, 100 lg/ml streptomycin (all
from Gibco BRL, Life Tecnologies, Scotland) at 37 C in humidiﬁed
atmosphere (5% CO2 in air). Cells were treated with Doxorubicin
(Doxo), Daunomicin (Dauno) or Quercetin (Qu) (Sigma–Aldrich,
St. Louis, USA), all at the ﬁnal concentration of 100 lM for 24 and
48 h, and then analyzed by ﬂow cytometry.
2.3. Detection of mitochondrial membrane potential (DWm)
Cells were stained with the DWm-sensitive probe JC-1 (ﬁnal concen-
tration 10 lM), as described [17].
2.4. Detection of DNA content in living cells
Hoechst 33342 was used to measure DNA content in living, intact
cells thanks to its capability to bind sequences of 3 AT base pairs
[18]. When excited by UV, it emits at 455 nm and allows the quantiﬁ-
cation of DNA content. Cells were stained with 5 lM Hoechst 33342
at 37 C for 30 minutes in complete medium without FCS and imme-
diately analyzed. Those with the typical hypodiploid peak were consid-
ered apoptotic.
2.5. Flow cytometry
DWm and apoptosis were analyzed by a Cyﬂow ML (from Partec
GmbH, Mu¨nster, Germany), equipped with a solid state blue laser
(emitting at 488 nm, 200 mW, kept at 50 mW), a UV Mercury lamp
HBO (100 long life, 100 W) and a red diode laser (635 nm, 25 mW).
Data were analyzed by Partec Flomax 3.0 and WinMDI softwares,
under Windows XP.Fig. 1. Cytoﬂuorimetric analysis of PBMC from a DS patient. Representativ
panels) and apoptosis (lower panels) in PBMC from a DS child after 48 h o2.6. mtDNA quantiﬁcation
DNA was extracted from 5 · 106 PBMC using the QIAamp DNA
Mini Kit (QIAGEN) according to the manufacturer’s protocols and
stored at 20 C until use. Content of mtDNA per cell was measured
by using Mitochondrial DNA qPCR kit (from GeneMoRe Italy srl,
Modena, Italy) as described [19].2.7. Statistical analysis
Statistical analyses were performed by two-tail Student t-test, using
the software Prism 3.03 under Windows XP. A P value <0.05 was con-
sidered signiﬁcant.3. Results
3.1. Cells from DS patients show a higher loss of
mitochondrial membrane potential (DWm)
Fig. 1 shows a representative example of changes in DWm
(upper panels) and apoptosis (lower panels) in Doxo-treated
PBMC from a DS patient. As shown in Fig. 2, after 24 (upper
panel) and 48 h (lower panel) of treatment Doxo, Dauno and
Qu induced a signiﬁcant loss of DWm in PBMC of both DS pa-
tients and healthy donors. No signiﬁcant diﬀerences in the per-
centage of cells with depolarized DWm were present between
the two groups after 24 h of treatment. However, after 48 he example of cytoﬂuorimetric analysis showing changes in DWm (upper
f incubation with 100 lM doxorubicin.
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Fig. 2. Changes in DWm in cells from DS and healthy children.
Percentage of PBMC from DS children and healthy donors (HD) with
low DWm after 24 (upper panel) and 48 (lower panel) hours of
incubation with doxorubicin (DOXO), daunomicin (DAUNO), quer-
cetin (QU), or no stimulus (CTRL). Values are expressed as
means ± S.E.M. HD vs. DS: *P < 0.05; **P < 0.005.
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Fig. 4. Mitochondrial DNA content in PBMC from DS and healthy
children. Mitochondrial DNA content is expressed as copies of
mtDNA per cell in PBMC from DS and control healthy donors
(HD). Values are expressed as means ± S.E.M. No statistical diﬀerence
was present between the two groups.
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subjects showed a consistent increase in the percentage of cells
with a relevant loss of DWm when compared to cells from con-
trol children (for Doxo: P = 0.008; Dauno: P = 0.004; Qu:
P = 0.013).
3.2. Cells from DS do not display an increased tendency to
undergo apoptosis
As shown in Fig. 3, after 24 (upper panel) and 48 h (lower
panel) of treatment Doxo, Dauno and Qu induced a consistent
apoptosis in both DS and healthy subjects. However, even if a%
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Fig. 3. Apoptotic nuclei in DS and healthy children. Percentage of
apoptotic nuclei in PBMC cultures from DS children and healthy
donors (HD) after 24 (upper panel) and 48 (lower panel) hours of
incubation with doxorubicin (DOXO), daunomicin (DAUNO), quer-
cetin (QU), or no stimulus (CTRL). Values are expressed as
means ± S.E.M. In no case comparison between DS and HD revealed
a statistical signiﬁcance.higher tendency was noted in cells from DS patients after 48 h
of culture, in no case the diﬀerence between the two groups of
donors was signiﬁcant.
3.3. mtDNA quantiﬁcation
We ﬁnally measured the amount of mtDNA in PBMC from
DS patients and healthy children, and found that they had a
comparable number of copies of mtDNA per cell (Fig. 4).4. Discussion
Changes in mitochondrial functionality and increased apop-
tosis have been described in patients aﬀected by DS. These
alterations have been found in neurons, whose degeneration
is supposed to be responsible for the precocious onset of Alz-
heimer disease, which typically aﬀects DS individuals after the
age of 35–40 years [20], in whom b-amiloid is over-expressed
[21].
Little is known on the presence of mitochondrial damages
and tendency to undergo apoptosis in peripheral blood cells
from DS individuals, who present profound alterations in
the distribution of several lymphocyte subpopulations
[22,23]. DS patients present a high risk of developing patholo-
gies of the immune system, such as autoimmune diseases or
leukaemia [24,25]. Complex changes of the normal cellular
homeostasis exist that could explain, at least in part, these
pathologies. On the one side, autoimmunity can result from
a decreased apoptosis of potentially autoreactive lymphocytes
that are generated during the process of intrathymic negative
selection, or to the loss of peripheral tolerance by mature T
lymphocytes. On the other hand, tumour cells, including leuke-
mic lymphocytes, are often characterized by the increased
expression and activity of anti-apoptotic genes, that are
responsible for the increased resistance to a variety of apopto-
genic stimuli.
Whenmitochondria are involved in the apoptotic process, one
of the possible events is a precocious loss of DWm, followed by
the release of cytochrome c and AIF, leading to caspase activa-
tion, which in turn causes to the degradation of nuclear DNA.
We analyzed the susceptibility to undergo apoptosis and
changes in DWm in peripheral blood cells from children with
DS, compared to age-matched healthy controls, either in basal
conditions or in response to diﬀerent agents (daunomycin,
524 E. Roat et al. / FEBS Letters 581 (2007) 521–525doxorubicin), or to a natural ﬂavonoid such as quercetin, that
have a strong pro-apoptotic eﬀect [26,27].
We found that, after 24 h of incubation, PBMC from DS
and controls showed a comparable percentage of cells with
low DWm. After 48 h, the treatment with toxic substances in-
creased the number of cells with low DWm both in DS and con-
trol cells, but such eﬀect was much stronger in DS. This
indicates that mitochondria from DS patients had a higher
sensitivity to damaging agents, in agreement with what found
by other authors. Indeed, studies on astrocytes from DS sub-
jects demonstrated a lower DWm and a decrease in mitochon-
drial redox activity compared to control cells [28]. This
observation, along with others reporting an impairment in
mitochondrial redox activity, could explain the lower DWm dis-
played by PBMC from DS subjects after incubation with
apoptogenic substances.
We found that PBMC from DS and healthy controls have a
similar tendency to undergo apoptosis, even if DS mitochon-
dria were more sensitive to several damaging agents. Thus,
since DS cells with altered mitochondrial function do not un-
dergo apoptosis, it might be hypothesized that DS patients
tend to maintain damaged cells, or that they have a higher
capacity to repair functional damages. It remains to be estab-
lished if and how this phenomenon can be linked to the devel-
opment of autoimmunity or neoplastic disorders.
A decrease in mtDNA content leads to an impaired produc-
tion of enzymes of the respiratory chain, with a consequent
reduction in the production of ATP, and a subsequent alter-
ation in cellular metabolism. Therefore, to investigate the pos-
sibility that an increased sensitivity of mitochondria to
apoptogenic agents was due to alterations in the amount of
mtDNA, we have quantiﬁed the number of copies of mtDNA
per cell in PBMC from DS and controls. This represent a new
information since, to our knowledge, no data are currently
present in literature about analysis of mtDNA copy number
in DS patients. Changes in mtDNA content from DS cells
could be expected also because such alterations have been re-
ported during the aging process and DS is characterized by
precocious aging. We have found that all donors had the same
amount of mtDNA, but it has to be underlined that the donors
we could analyze were very young, and thus it might be that
alterations in the synthesis and changes in the amount of
mtDNA could be detectable only in older patients, after sev-
eral years of exposure to ROS, causing mtDNA alterations.
Moreover, most PBMC have a relatively short half life, as they
are constantly renewed in the body; this could be a limiting
factor in revealing diﬀerences in mtDNA synthesis. Thus, it
would be extremely interesting to measure mtDNA in cells
with a longer life, that are chronically exposed to mitochon-
drial damages.
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